Cytomegalovirus prophylaxis in antibody-treated renal transplanted patients.
Department of Nephrology, Odense University Hospital, Denmark.
S
S
Birkeland
B
B
Gahrn-Hansen
H
H
Andersen
N
N
Rohr
K E
KE
Larsen
A
A
Jørgensen
D000212:Acyclovir / Q000008:administration & dosage; D000328:Adult; D000961:Antilymphocyte Serum / Q000009:adverse effects; D002648:Child; D016572:Cyclosporine / Q000009:adverse effects; D003586:Cytomegalovirus Infections / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D015774:Ganciclovir / Q000008:administration & dosage; D006084:Graft Rejection / Q000209:etiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000276:immunology / Q000502:physiology; D016853:Muromonab-CD3 / Q000009:adverse effects; D014019:Tissue Donors
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D016572:Cyclosporine; D015774:Ganciclovir; D000212:Acyclovir